Overview

Study of Pomalidomide in Anal Cancer Precursors

Status:
Active, not recruiting

Trial end date:
2022-01-31

Target enrollment:

Participant gender:

Summary

This is a single centre open label phase II trial to determine the antitumor efficacy of the oral immunomodulatory agent pomalidomide in persistent human papillomavirus (HPV) -associated high grade squamous intra-epithelial lesions (HSIL) in patients with and without human immunodeficiency virus (HIV) infection.

Phase:

Phase 2

Details

Lead Sponsor:

Kirby Institute

Treatments:

Pomalidomide
Thalidomide